AHPA charters Psychedelic Plants and Fungi Committee

The committee was established to address issues related to the safe use and responsible commerce of lawfully marketed products derived from psychedelic plants and fungi.

The American Herbal Products Association’s (AHPA; Silver Spring, MD) Board of Trustees has charted the AHPA Psychedelic Plants and Fungi Committee to address issues related to the safe use and responsible commerce of lawfully marketed products derived from psychedelic plants and fungi. Elan Sudberg, CEO of Alkemist Labs was appointed the committee’s first chair.

“With the emergence of legal psychedelics being professionally used to address major mental health issues, and research finding significant benefits in that context, it’s crucial that the category be developed with experience and deliberation,” said Sudberg, in a press release. “Given that AHPA's mission is to promote the responsible and sustainable commerce of herbal products to ensure that consumers have informed access to a wide variety of safe herbal goods, it’s entirely appropriate that AHPA’s expertise be utilized to help that sector grow responsibly.”